Introduction
Donepezil is a selective, reversible inhibitor of acetylcholinesterase, and is used for treatment of Alzheimer's disease. Although donepezil is generally well tolerated, there are some reports of side effects associated with cholinergic effect. In addition, it has been reported that donepezil may cause cardiac toxicity, such as QT prolongation (Takaya et al., 2009 ). There are also case reports of cardiac toxicity of donepezil in patients concurrently receiving cilostazol, benidipine or memantine (Tanaka et al., 2009; Shinozaki, 2012; Igeta et al., 2013) . However, the mechanism of the putative drug-drug interaction (DDI) has not yet been clarified, even though donepezil is often administered with other drugs, since it is frequently prescribed for elderly people. On the other hand, it has been proposed that co-administration of donepezil with cilostazol is more effective in patients with mild dementia (Ihara et al., 2014) and this was supported by findings in an animal model (Lee et al., 2007) . Accordingly, it is important to examine whether interaction of donepezil with cilostazol might occur, and if it does, whether it might have clinical relevance.
Pharmacological activity usually depends on the unbound drug concentration at the site of action.
Since donepezil shows high bioavailability after oral administration (more than 90% in rats) (Matsui et al., 1999) , it is unlikely that co-administered cilostazol increases intestinal absorption of donepezil.
Clearance of donepezil is mainly due to metabolism via CYP3A4 and partly via CYP2D6, so interaction of the two drugs at drug-metabolizing enzymes could contribute to increased systemic exposure to donepezil; however, the increase of plasma concentration of donepezil by ketoconazole, a typical inhibitor of CYP3A4, was reported to be mild, amounting to at most 30% (Tiseo et al., 1998a) . Another possibility is an increase in distribution to heart tissue. Transporters are involved in drug absorption, tissue distribution and excretion, and DDI at transporters can cause significant changes in plasma concentrations of affected drugs; on the other hand, DDI at transporters involved in tissue distribution, such as P-glycoprotein (ABCB1) and breast cancer resistance protein (BCRP, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 14, 2015 as DOI: 10.1124 at ASPET Journals on June 21, 2017 dmd.aspetjournals.org Downloaded from DMD # 66654 5 ABCG2), may alter the tissue distribution without any apparent change in plasma concentration (Sadeque et al., 2000; Sasongko et al., 2005) . Accordingly, we considered that, if the distribution of donepezil to heart tissue is regulated by efflux transporters, and if the efflux process is inhibited by cilostazol, accumulation of donepezil in the tissue might be increased. P-Glycoprotein is expressed in endothelium of heart tissue and could serve to limit drug distribution to the heart (Meissner et al., 2002) . A significant increase in the distribution of vinblastine to heart tissue was observed in mdr1a gene-knockout mice, demonstrating that P-glycoprotein is functional in heart tissue to exclude substrate drugs (Schinkel et al., 1994) . In addition, QT prolongation by romidepsin was suggested to be influenced by allelic variation of the ABCB1 gene, suggesting that P-glycoprotein contributes to the blood-heart barrier (Sissung et al., 2010) . Previous reports on the transport of donepezil by P-glycoprotein are conflicting: values of efflux ratio ranging from unity to 2.3 have been found in P-glycoprotein-expressing Madin-Darby canine kidney (MDCK) cells (Summerfield et al., 2007; Lili et al., 2013 ). An in vivo study in mice suggested that donepezil distribution to brain is controlled by P-glycoprotein, based on the increase of accumulation by cyclosporine A (Ishiwata et al., 2007) . Furthermore, we have previously shown that cilostazol efflux transport is mediated by P-glycoprotein (Toyobuku et al., 2003) . Accordingly, it is possible that inhibition of P-glycoprotein by cilostazol would lead to increased accumulation of donepezil in the heart if donepezil is clearly shown to be a substrate of P-glycoprotein. In addition to P-glycoprotein, BCRP is also expressed in heart, mainly in capillary endothelial cells and cardiomyocytes (Meissner et al., 2006; Solbach et al., 2008; Higashikuni et al., 2010; Emmert et al., 2013) , and thus BCRP is also a potential site of DDI. However, it has not been reported whether donepezil is a substrate of BCRP.
In the present study, we aimed to examine our hypothesis that cardiotoxicity associated with co-administration of donepezil and cilostazol is a result of interaction of the two drugs at efflux This article has not been copyedited and formatted. The final version may differ from this version. Inhibitors of BCRP and P-glycoprotein were added to both the apical and basolateral sides during pre-incubation and incubation. When transport reaction was initiated, 0.5-mL and 1.5-mL aliquots of transport medium were added to the apical and basolateral sides of the Transwell insert membrane, respectively. Transport of donepezil was measured in both directions, apical (AP)-to-basolateral (BL) and basolateral-to-apical side. Receiver side solution (100 µL) was withdrawn for measurement of transport and replaced with an equal volume of transport medium at 15, 30, 45, and 60 min.
All the drugs used were quantitated by HPLC analysis. Before HPLC analysis, the sample was mixed vigorously with 100 µL of acetonitrile for 1 min, and then centrifuged at 15,000 rpm and 4°C
for 15 min. The supernatant was transferred to a 1.5 mL polypropylene microcentrifuge tube and evaporated to dryness. The residue was reconstituted in 100 µL of the mobile phase used for HPLC analysis.
The apparent permeability (P app , cm/sec) of donepezil across the cell monolayer was calculated using the following equation:
where Q is the amount of donepezil transported over time t. C is the initial concentration in the donor side and A is the surface area of the membrane used.
Kinetic parameters were estimated by means of nonlinear least-squares analysis using the MULTI program (Yamaoka et al., 1981) . The inhibitory effect of cilostazol on donepezil or quinidine transport was expressed as a percentage of the control, and the inhibitor concentration giving half-maximum inhibition (IC 50 ) was obtained by applying the following equation:
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where v and C are transport rate and initial concentration of donepezil, respectively.
In vitro tissue accumulation study using rat heart slices
The accumulation study of donepezil in heart slices from male Wistar rats was conducted as described previously, with some modifications (Iwata et al., 2008) . Briefly, rats were anesthetized with ether and exsanguinated from the descending aorta. The heart was immediately excised and rinsed with ice-cold saline. Atrium and connective tissue were removed carefully, and the heart was sectioned at 350 µm with a microslicer (Zero 1, Dosaka EM Co. Ltd., Kyoto, Japan). The heart slices were pre-incubated with ice-cold test solution containing 120 mM NaCl, 16.2 mM KCl, 1 mM CaCl 2 , 1.2 mM MgSO 4 , 10 mM NaH 2 PO 4 /Na 2 HPO 4 (pH 7.5) and oxygenated by bubbling with 99.5% O 2 gas. After pre-incubation, the heart slices were incubated with donepezil at 37°C for 30 min with bubbling of 99.5% O 2 . Inhibitors used were present during both pre-incubation and incubation. At appropriate times, slices were picked up from the solution containing donepezil, and rinsed with This article has not been copyedited and formatted. The final version may differ from this version. ice-cold saline. They were blotted to dryness, weighed and homogenized with 2 mL of water using a homogenizer (ULTRA TURRAX T25, Ika). The obtained homogenate (500 µL) was transferred to a 1.5 mL polypropylene microcentrifuge tube and 500 µL of acetonitrile was added to it. The samples were vortexed for 1 min and centrifuged at 15,000 rpm and 4°C for 15 min. The supernatant was evaporated to dryness and the resultant residue was reconstituted in 100 µL of the mobile phase used for HPLC analysis.
Extracellular adhered water space was evaluated in terms of apparent uptake of [ All the accumulation values were expressed as slice-to-medium concentration ratio, obtained by dividing the accumulated amount in the heart slices by the final concentration in the medium and the weight of tissue slices.
In vivo animal study
Female Wistar rats were used in the in vivo animal study. For preparation of dosing solution, donepezil was dissolved in saline and cilostazol was suspended in methylcellulose solution (0.5%, w/v). Cilostazol (100 or 500 mg/kg body weight) was administered to rats orally 30 min before intravenous administration of donepezil. When donepezil (1 mg/kg body weight) and elacridar (1 mg/kg body weight) were co-administered to rats intravenously, donepezil was dissolved in a mixture of saline and polyethyleneglycol 600 (3:1, v/v). The volumes of oral and intravenous administration were 3 and 1 mL/kg body weight, respectively. Elacridar was dissolved in dimethylsulfoxide (DMSO) and diluted in a mixture of saline and polyethyleneglycol 600. The blood This article has not been copyedited and formatted. The final version may differ from this version. was collected from the jugular vein at 0.5, 1, 2, and 3 hr after intravenous administration of donepezil to rats. The plasma was obtained by centrifugation of the blood at 5,000 rpm and 4°C for 10 min. Rats were sacrificed 3 hr after administration of the donepezil by anesthesia with ether followed by exsanguination. The whole heart and brain tissues were immediately excised and frozen at -30°C until analysis. Frozen heart and brain samples were thawed, weighed and homogenized with 2 mL of water using a homogenizer. Before HPLC analysis, 500 µL of homogenate was transferred to a 1.5 mL disposable microcentrifuge tube and 500 µL of acetonitrile was added to deproteinize the tissue. The samples were vigorously mixed for 1 min and centrifuged at 15,000 rpm and 4°C for 15 min. The resultant supernatant was evaporated to dryness, and the residue was reconstituted in 100 µL of the mobile phase used for HPLC analysis.
Pharmacokinetic analysis of the plasma profiles after intravenous administration was performed with the MULTI program using a one-compartment model according to the following equation:
where C p is the plasma concentration of donepezil. V d is the volume of distribution, k e is a first-order elimination rate constant and t is time after administration. CL tot (total clearance) was obtained by applying the following equation:
where AUC 0-∞ is the area under the plasma concentration-time curve extrapolated to infinity.
Analytical methods
The concentrations of drugs were quantified by HPLC. An HPLC system (Waters Co., Milford, All the data are presented as the mean ± S.E.M. or S.D. Statistical significance was evaluated by means of Student's t-test with P < 0.05 as the criterion for a statistically significant difference.
Results

Transcellular transport of donepezil in MDCK cells
To examine whether donepezil is a substrate of efflux transporters, transcellular transport of donepezil by MDCK cells expressing BCRP or P-glycoprotein was compared with that in Mock cells. Figure 1A shows the time course of donepezil (3 M) transport in the apical (AP)-to-basolateral (BL) and basolateral-to-apical directions in the three types of MDCK cells cultured on Transwell inserts. Figure 1B shows the apparent permeability of donepezil obtained from the slope of the results shown in Fig. 1A . In Mock cells, there was no difference between the basolateral-to-apical and apical-to-basolateral transport of donepezil. However, basolateral-to-apical transport in MDCK cells expressing BCRP or P-glycoprotein was significantly higher than that in the opposite direction. These results demonstrate that donepezil is a substrate of both BCRP and P-glycoprotein.
Inhibitory effect of cilostazol on transport activity of P-gp and BCRP
We first examined whether cilostazol is an inhibitor of P-glycoprotein and/or BCRP, using MDCK cells in the presence of increasing concentrations of cilostazol. The results are shown in Fig. 2 . In the case of P-glycoprotein, donepezil transport was insufficient to enable quantitative analysis of the inhibitory effect of cilostazol, so quinidine was used as the substrate of P-glycoprotein. In the case of BCRP, donepezil was used as the substrate. Cilostazol inhibited P-glycoprotein-mediated transport of quinidine (5 M) with the IC 50 of 12.7±0.22 µM. The obtained IC 50 is much higher than the observed unbound plasma concentration of cilostazol (143 ~ 203 nM) at clinically used dose levels (Suri et al., 1998 
Concentration dependence of BCRP-mediated donepezil transport
To elucidate whether BCRP-mediated donepezil transport is clinically important, we examined the affinity of donepezil for BCRP. Figure 3 Since the obtained Km value is higher than maximum concentration of donepezil in plasma (70 nM) at clinically used dose levels (Tiseo et al., 1998b) , BCRP-mediated transport of donepezil would not be saturated under these conditions.
Effect of cilostazol and Ko143 on in vitro accumulation of donepezil in heart tissue slices
To examine the effect of cilostazol on donepezil distribution to the heart, we measured accumulation of donepezil in rat heart tissue slices. In this study, BCRP inhibitor Ko143 (0.1 M)
and cilostazol (5 M) were used. Figure 4 shows the accumulation of donepezil at 0.1 M in heart tissue slices at 30 min. When heart tissue slices were incubated with donepezil in the presence of cilostazol, the accumulation (evaluated in terms of slice-to-medium concentration ratio) of donepezil was significantly increased as compared to the control (from 4.78 to 5.95). Similarly, when accumulation of donepezil in heart slices was examined in the presence of Ko143 as a BCRP inhibitor, a significant increase was again observed (from 4.78 to 5.78). These results suggest that the increase of donepezil accumulation in heart can be accounted for by the inhibition of BCRP by This article has not been copyedited and formatted. The final version may differ from this version. 
Effects of cilostazol and elacridar on disposition of donepezil in rats
The in vivo effect of cilostazol on the disposition of donepezil was examined in rats. Figure 5 shows the plasma concentration-time curve of donepezil in female rats after bolus intravenous administration of 1 mg/kg, with and without cilostazol (100 mg/kg or 500 mg/kg) or elacridar (1 mg/kg) as an inhibitor of both BCRP and P-glycoprotein. Table 1 summarizes the pharmacokinetic parameters of donepezil obtained by one-compartment model analysis. There were no significant differences in plasma concentration between the control rats and cilostazol-or elacridar-treated rats at each measured time (Fig. 5 ). In addition, no significant change in total clearance (CL tot ), volume of distribution (V d ) or plasma AUC was observed in the case of coadministration of cilostazol or elacridar (Table 1) . Here, plasma total concentrations of cilostazol at 100 and 500 mg/kg doses were 8.54 ± 0.67 and 16.7 ± 3.85 M, respectively, at 3.5 hr after oral administrations, and that of elacridar was 9.05 ± 1.05 M at 30 min after intravenous administration. Table 2 shows the concentration and tissue-to-plasma concentration ratio (Kp) in heart and brain tissues at 3 hr after intravenous administration with and without oral cilostazol or intravenous elacridar. The brain was measured as a reference, since BCRP and P-glycoprotein both function as a part of the blood-brain barrier. As mentioned above (Fig. 5) , the treatments caused no significant changes in plasma concentration of donepezil. However, cilostazol caused a concentration-dependent increase in Kp in both brain and heart. At the high dose of cilostazol, a statistically significant increase in Kp was observed in heart, from 6.32 to 7.82 (+24%), and in brain, from 7.67 to 9.47 (+23%). Similarly, elacridar significantly increased the Kp of donepezil from 5.5 to 7.92 (+44%) in heart and from 6.78 to 10.3 (+52%) in brain. In this study, observed plasma unbound concentrations of cilostazol at 3.5 hr after oral administration were 85.4 ± 6.7 nM and This article has not been copyedited and formatted. The final version may differ from this version. 167 ± 39 nM at doses of 100 and 500 mg/kg, respectively, using the reported plasma unbound fraction of 0.01 in rats (Kamada et al., 2011) , and that of elacridar at 30 min after 1 mg/kg intravenous administration was 181 ± 0.02 nM, using the plasma unbound fraction of 0.02 (Kallem et al., 2012 
Discussion
DDIs at efflux transporters such as P-glycoprotein and BCRP have been well documented to influence intestinal absorption and urinary and biliary elimination, while clinically relevant DDIs relating to the tissue distribution process is poorly understood. In the present study, we focused on the interaction of donepezil and cilostazol at efflux transporters as a potential explanation of the clinically reported cardiotoxicity of donepezil when co-administered with cilostazol (Tanaka et al., 2009; Shinozaki, 2012; Igeta et al., 2013) . This is an important issue, because simultaneous use of donepezil and cilostazol has been proposed to improve the pharmacological outcome (Ihara et al., 2014; Lee et al, 2007) .
We first confirmed that donepezil is a substrate of BCRP. It was also a substrate of P-glycoprotein, though there are conflicting reports as to the contribution of P-glycoprotein to donepezil transport (Summerfield et al., 2007; Lili et al., 2013) . Here, we modified the transport study method by adding TEA and serum albumin to the medium in order to minimize the effect of nonspecific binding and/or transport by other transporters natively expressed in host cells, since donepezil is a substrate of several organic cation transporters that might be functional in MDCK cells, and thus might disturb quantitative analysis of donepezil transport by P-glycoprotein and/or BCRP. In the presence of TEA and serum albumin, unidirectional transport by P-glycoprotein and BCRP was clearly demonstrated (Fig. 1) .
We used this modified method to examine the inhibitory potential of cilostazol on donepezil transport by P-glycoprotein and BCRP. Interestingly, both P-glycoprotein and BCRP were inhibited by cilostazol, though the IC 50 for P-glycoprotein (12.7 M) was much higher than that for BCRP (1.3/0.13), which is much higher than the critical value of 0.1. However, in the case of P-glycoprotein, the ratio is 0.102, which is a borderline value, suggesting a low risk of DDI at P-glycoprotein. If the total concentration of cilostazol is replaced with the unbound concentration, the [I] 1 /IC 50 ratio at BCRP is 0.5 based on plasma protein binding of cilostazol of about 95% in humans (Suri et al., 1998) , and this is still within the range of drug interaction risk. In addition, a total Cmax of 3.32 M (unbound Cmax: 0.166 M) was reported in certain populations of patients who take cilostazol (Suri et al 1998) , and in this case the [I] 1 /IC 50 ratio is higher than unity. Thus, we cannot rule out interaction of cilostazol at BCRP clinically. On the other hand, the clinically relevant plasma concentration of donepezil (70 nM, Tiseo et al., 1998b ) is much lower than the Km of BCRP-mediated transport of donepezil (4.03 M, Fig. 3 ), which means that BCRP is not saturated in the clinical setting and can efficiently transport donepezil. These results indicate that in vivo DDI of donepezil and cilostazol at BCRP could be clinically significant in humans.
We then conducted an animal study to confirm the influence of cilostazol on the tissue distribution of donepezil. Firstly, in vitro accumulation of donepezil in heart tissue slices at the steady state was increased in the presence of cilostazol (5 M) as well as Ko143 (0.1 M), a selective BCRP inhibitor (Fig. 4) . Although the extent of the increase in Kp value is not so high (24% of the control), the increment of Kp is more than 1.1 (from 4.78 to 5.95), which can be quantitatively considered as a significant increase. BCRP is localized at endothelial cells and cardiomyocytes in heart (Solbach et al., 2008; Meissner et al., 2006) . It is not clear whether this localization of BCRP in heart tissue is well reflected in the currently used tissue slice method, since the tissue surface might be exposed to This article has not been copyedited and formatted. The final version may differ from this version. the drug solution directly, and BCRP may not be able to exclude donepezil as efficiently as it would in its role as a tissue barrier transporter in intact tissue. However, the observation of significantly increased accumulation of donepezil in the heart in the presence of BCRP inhibitor Ko143, to an extent comparable with the effect of cilostazol, indicates that BCRP is at least partly functional under the conditions of our experimental method. Accordingly, it is reasonable to conclude that cilostazol increases donepezil accumulation in heart tissue by inhibiting BCRP.
The in vivo pharmacokinetic study indicated an increase in Kp of donepezil in both heart and brain in the presence of cilostazol. Here, as the control inhibitor, we used elacridar, which inhibits both BCRP (IC 50 : 252 nM) and P-glycoprotein (IC 50 : 4 nM) depending on the concentration (Kwak et al., 2010) , since a previous study showed clear in vivo inhibition of P-glycoprotein at the blood-brain barrier after intravenous administration (Kallem et al., 2012) . The increments of Kp of donepezil in heart and brain by elacridar were 44% and 52%, respectively (Table 2) . Since the observed plasma unbound concentration of elacridar was 181 nM in the present study at 30 min after administration, the observed concentration was considered sufficiently high to inhibit P-glycoprotein completely and BCRP partially. The effect of cilostazol was dose-dependent with significant increases of 24% and 23% in heart and brain, respectively, at the high dose of 500 mg/kg, though the increment was not statistically significant at the low dose of 100 mg/kg. Plasma total concentrations of cilostazol at the low and high doses were 8.54 and 16.7 M, respectively, and the unbound fraction in rat plasma was about 1% (Kamada et al., 2011) , so these doses are comparable with the unbound concentrations achievable at clinical doses in humans (1.35 to 2.7 M, Interview form of cilostazol). Considering the IC 50 values of cilostazol for BCRP and P-glycoprotein, 0.13 and 12.7 M, respectively, the plasma cilostazol concentration should be high enough to interact with BCRP at the high dose, but not with P-glycoprotein, as discussed above. Furthermore, higher tissue accumulation of donepezil than shown in Table 2 is possible, since the measured time point at 3 hr after females show higher plasma concentrations with a longer half-life (Kamada et al., 2011) , which is useful for the current study.
Another important point is an absence of any significant change in the pharmacokinetic parameters derived from plasma concentrations, despite the significant increase of Kp in both heart and brain.
Although donepezil is transported by BCRP and P-glycoprotein, their contributions to the overall elimination of donepezil are likely to be small, since metabolism by CYP3A4 and CYP2D6
dominates in elimination. Cilostazol is eliminated mainly through metabolism by CYP3A4 and CYP3A5, but the Km values (from 1.6 to 5.6 M) are higher than the clinically achievable plasma total concentration of cilostazol (Hiratsuka et al., 2007) . Accordingly, cilostazol is expected to have only a minimal effect on metabolism of donepezil, which is consistent with the results of the present study in rats. The reason why no change in plasma concentration was observed in spite of the increased accumulation in tissues such as brain and heart would be that the amounts of donepezil distributed to these tissues are too small to affect the plasma concentration, due to the small contribution of these tissues to the total distribution volume. Accordingly, this type of DDI at efflux transporters involved in the tissue distribution process should be carefully considered, since local tissue concentration can be significantly increased without any apparent change in systemic exposure.
In conclusion, donepezil was found to be a substrate of both P-glycoprotein and BCRP. Cilostazol This article has not been copyedited and formatted. The final version may differ from this version. Table 2 Plasma and tissue (brain and heart) concentrations and Kp of donepezil at 3 hr after intravenous administration with and without cilostazol or elacridar in rats.
Donepezil concentrations in plasma, heart, and brain were measured at 3 hr after intravenous administration as described in the footnote of Table 1 . The results are shown as mean and S.D (n = 3).
Kp was obtained by dividing tissue concentration by plasma concentration. In the case of elacridar, the control rats were administered DMSO under the same conditions as used for the rats treated with elacridar.
*: significantly different from control value by Student's t-test (P < 0.05).
